

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

Study Number:

Study Gender:

PWG Approval Date:

Version:

I05: Clinical Observations Summary

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

I10482B

Both

See web page for date of PWG Approval

v1.1.2

Date Report Requested: 11/25/2020

Time Report Requested: 07:46:41

Lab: Burleson Research Technologies

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I05: Clinical Observations Summary

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 11/25/2020

Time Report Requested: 07:46:41

Lab: Burleson Research Technologies

F0 Female

Phase	Observation	Treatment Groups (ppm)			
		0	250	500	1000
LD	Discharge Eye; Red, Right	1 / 30 LD 2	0 / 29	0 / 30	0 / 29

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I05: Clinical Observations Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 11/25/2020

Time Report Requested: 07:46:41

Lab: Burleson Research Technologies

F1 Male: SRBC

Phase	Observation	Treatment Groups (ppm)				
		0	250	500	1000	15 mg/kg CPS
SD	Discharge Eye; Red, Right	0 / 12	0 / 12	0 / 12	1 / 12 SD 42	0 / 8
SD	Missing Tip of Tail	0 / 12	0 / 12	0 / 12	1 / 12 SD 49	0 / 8

Study Number: I10482B
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

I05: Clinical Observations Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 11/25/2020
Time Report Requested: 07:46:41
Lab: Burleson Research Technologies

F1 Female: SRBC

Phase	Observation	Treatment Groups (ppm)				
		0	250	500	1000	15 mg/kg CPS
SD	Wound Flank; Left	0 / 12	0 / 12	0 / 12	1 / 12 SD 7	0 / 8

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I05: Clinical Observations Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 11/25/2020

Time Report Requested: 07:46:41

Lab: Burleson Research Technologies

F1 Male: KLH

Phase	Observation	Treatment Groups (ppm)				
		0	250	500	1000	15 mg/kg CPS
SD	Discharge Eye; Left, Red	0 / 12	0 / 12	2 / 12 SD 49	0 / 12	0 / 8
SD	Discharge Eye; Red, Right	1 / 12 SD 42	0 / 12	0 / 12	0 / 12	0 / 8
SD	Discharge Eye; Right	0 / 12	0 / 12	0 / 12	1 / 12 SD 56	0 / 8

Study Number: I10482B
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

I05: Clinical Observations Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 11/25/2020
Time Report Requested: 07:46:41
Lab: Burleson Research Technologies

F1 Female: KLH

Phase	Observation	Treatment Groups (ppm)				
		0	250	500	1000	15 mg/kg CPS
SD	Kinked Tail	0 / 12	0 / 12	0 / 12	1 / 12 SD 0	0 / 8

Study Number: I10482B
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

I05: Clinical Observations Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 11/25/2020
Time Report Requested: 07:46:41
Lab: Burleson Research Technologies

F1 Male: Immunophenotyping

Phase	Observation	Treatment Groups (ppm)				
		0	250	500	1000	15 mg/kg CPS
SD	Kinked Tail	0 / 12	0 / 12	0 / 12	1 / 12 SD 0	1 / 8 SD 40

Study Number: I10482B
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

I05: Clinical Observations Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 11/25/2020
Time Report Requested: 07:46:41
Lab: Burleson Research Technologies

F1 Female: Immunophenotyping

Phase	Observation	Treatment Groups (ppm)				
		0	250	500	1000	15 mg/kg CPS
SD	Alopecia Head; Bilateral	1 / 12 SD 7	0 / 12	0 / 12	0 / 12	0 / 8
SD	Kinked Tail	0 / 12	0 / 12	0 / 12	1 / 12 SD 0	1 / 8 SD 40
SD	Scab Head; Bilateral	1 / 12 SD 14	0 / 12	0 / 12	0 / 12	0 / 8

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I05: Clinical Observations Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 11/25/2020

Time Report Requested: 07:46:41

Lab: Burleson Research Technologies

F1 Male: CTL

Phase	Observation	Treatment Groups (ppm)				
		0	250	500	1000	15 mg/kg CPS
SD	Discharge Eye; Bilateral, Red	1 / 12 SD 28	0 / 12	0 / 12	0 / 12	0 / 8

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I05: Clinical Observations Summary

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 11/25/2020

Time Report Requested: 07:46:41

Lab: Burleson Research Technologies

F1 Female: CTL

Phase	Observation	Treatment Groups (ppm)				
		0	250	500	1000	15 mg/kg CPS
SD	Discharge Eye; Red, Right	1 / 12 SD 0	0 / 12	0 / 12	0 / 12	0 / 8

Study Number: I10482B
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

I05: Clinical Observations Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 11/25/2020
Time Report Requested: 07:46:41
Lab: Burleson Research Technologies

F1 Male: Immunopathology

Phase	Observation	Treatment Groups (ppm)				
		0	250	500	1000	15 mg/kg CPS
SD	Discharge Eye; Red, Right	0 / 12	0 / 12	0 / 12	0 / 12	1 / 8 SD 40

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I05: Clinical Observations Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 11/25/2020

Time Report Requested: 07:46:41

Lab: Burleson Research Technologies

F1 Female: Immunopathology

Phase	Observation	Treatment Groups (ppm)				
		0	250	500	1000	15 mg/kg CPS
SD	No Abnormalities Found	12 / 12	12 / 12	12 / 12	12 / 12	8 / 8

Study Number: I10482B

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

I05: Clinical Observations Summary
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 11/25/2020

Time Report Requested: 07:46:41

Lab: Burleson Research Technologies

LEGEND

Animals exhibiting clinical observations "within normal limits" were recorded as scheduled but are omitted from the table for clarity.

Upper row displays cumulative number of animals with observation / total animals started on study for SD days, total number of pregnant animals for GD days, or total number of littered females for LD days.

Lower row displays day of observation onset

SD – Study Day; GD – Gestation Day; LD – Lactation Day; PND – Postnatal Day, adults post-weaning

F0 females listed as SD were not pregnant.

CPS = Cyclophosphamide

**** END OF REPORT ****